Key Points to Consider When Evaluating Andexxa for Formulary Addition
By Harry Peled, Nhu Quyen Dau, Helen Lau
As featured in Neurocritical Care Journal

In May 2018, Andexxa received accelerated approval from the FDA as a specific reversal for rivaroxaban- and apixaban-treated patients with life-threatening or uncontrolled bleeding despite not establishing improvement in hemostasis. The recent publication of ANEXXA-4 and the wider availability for Andexxa in 2019 has led many hospital Pharmacy and Therapeutics (P&T) committees to discuss whether Andexxa should be added to formulary.
NEWS: Vitamin C Infusion in Sepsis and Severe Acute Respiratory Failure (the CITRIS-ALI Trial)
By Fowler AA, Truwit JD, Hite RD, et al. Reviewed by: Kyle Hobbs, MD 
As featured in Currents
Acute respiratory distress syndrome (ARDS) often accompanies sepsis and contributes to significant morbidity and mortality ...
ASQC: How to Form a Cohesive Team and Give Feedback to Trainees
By Christa O’Hana S. Nobleza, MD, MSCI; Aleksandra Yakhkind, MD, MS; Chitra Venkatasubramanian, MBBS, MD, MSc, FNCS
As featured in Currents

Do you have questions regarding your professional life? The Trainee and WINCC Sections have teamed up to publish a column to serve your professional advice needs ...
Greenville Memorial Hospital’s Unified Neuro ICU Continues to Grow
By Ryan Hakimi, DO, MS, FNCS, NVS
As featured in Currents

With the support of Fredy J. Revilla, MD, and Charles Kanos, MD, the Chiefs of Neurology and Neurosurgery, respectively, a unified Neuro ICU Service was started at Prisma Health–Upstate's Greenville Memorial Hospital ...
View the Special Digital Issue of Currents
By Currents Editor
As featured in Currents
If you weren’t able to pick up your printed copy of Currents at the 17th Annual Meeting, you can view the digital edition of the publication online ...